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Testicular cancer is a highly curable disease that mainly affects men between
20 and 40 years of age. Nowadays, over 807o of patients become long-term
survivors following treatment with chemotherapy that consists of a
combination of bleomycin, etoposide, and cisplatin (BEP-regimen).
Unfortunately, vascular toxic effects of chemotherapy have been described in
testicular cancer patients in both the short and the long term. These vascular
complications may cause serious morbidity and sometimes mortality in
survivors who are generally young. Moreover, vascular toxicity occurring
during treatment may interfere with the continuation of a potentially curative
treatment and thus reduce the chance of cure. It is largely unknown how and in
which patients vascular toxicity wil l develop. However, this knowledge is
needed for the development of appropriate prevention strategies and for the
selection of high risk patients who are most likely to benefit from this.
In chapter 2, we described and discussed the development of a range of
metabolic disorders in survivors of various malignancies, including testicular
cancer, following multimodality cancer treatment. These metabolic disorders
include dyslipidaemia, overweight, and insulin resistance, which aÍe all
components of the so-called metabolic syndrome. The metabolic syndrome is
an important risk factor for the development of cardiovascular disease in the
general population. An increased risk for cardiovascular disease has also been
reported in long-term survivors of childhood malignancies and testicular
cancer. Therefore, the development of the metabolic syndrome in survivors of
cancer after multimodality treatment may be important. We described
association studies in the general population demonstrating correlations
between the components of the metabolic syndrome and hormonal deficiencies
(sex hormones, growth hormone, and thyroid hormone), hypomagnesaemia,
and endothelial dysfunction. We also described the development of these latter
disorders in cancer patients following curative treatment. Based on the co-
occurrence of metabolic disorders on the one hand and of hormonal
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deficiencies, hypomagnesaemia, and endothelial dysfunction on the other in
survivors of cancer, we hypothesized that these latter disorders play an
etiologic role in the development of the metabolic syndrome and, thus, increase
the risk of cardiovascular disease.
In chapter 3, we actually tested part of this hypothesis in long-term
survivors of testicular cancer. Chemotherapy had been previously associated
with an increased risk of either overt or compensated (normal total testosterone,
but elevated luteinising hormone levels) Leydig cell dysfunction. We wondered
whether the secretion of other hormones was disturbed as well and whether
hormonal disturbances were associated with the metabolic syndrome in these
men. We included 86 testicular cancer patients who had been cured with
unilateral orchidectomy and cisplatin-based chemotherapy and did not use
hormonal replacement therapy. These patients were compared with 44
testicular cancer patients with stage I disease who had been treated with
orchidectomy only and with 47 healthy men of comparable age. Presence of the
metabolic syndrome was determined using guidelines from the National
Cholesterol Education Program ATP III. Thyroid-stimulating hormone,
follicle-stimulating hormone (FSH), inhibin B, luteinising hormone (LH), total
testosterone, sex-hormone binding globulin, free testosterone, oestradiol,
dehydroepiandrosterone sulfate, and insulin-like growth factor 1 were
determined in blood. Furthermore, cortisol metabolite excretion was measured
in urine. The metabolic syndrome was present in 22 (267o) chemotherapy
patients, in l6 (367o) stage I patients and in four (97o) controls. Compared with
healthy controls, we found increased levels of LH, FSH and oestradiol, and
decreased levels of inhibin B and total and free testosterone in patients treated
with chemotherapy. Levels of adrenal, thyroid. and pituitary hormones did not
diÍÍèr. Total testosterone levels were lower and urinary cortisol metabolite
excretion was higher in chemotherapy-treated patients with the metabolic
syndrome than in those without. Chemotherapy-treated patients with the
metabolic syndrome also had a higher body mass index (BMI) before treatment
and a larger increase in BMI after treatment. Since total testosterone and
urinary cortisol metabolite excretion were also associated with BMI after
treatment, these hormones may. through this association, play a role in the
development of the metabolic syndrome and cardiovascular disease in
testicular cancer survivors.
Cardiovascular disease in testicular cancer survivors seems to develop after
more than ten years of follow-up especially. Detection of risk factors and still











































intervention with the aim to prevent cardiovascular events after longer follow-
up. In chapter 4, we investigated vascular structure and function to find out
whether early signs of atherosclerosis are already present in survivors of
testicular cancer during the first ten years of follow-up. We compared 90
chemotherapy-treated testicular cancer patients (median follow-up seven years)
with 44 patients treated with orchidectomy only and wtth 47 healthy men. The
same groups of patients and controls were described in chapter 3. We measured
24-h urinary albumin excretion and plasma levels of fibrinogen, high-
sensitivity C-reactive protein (hs-CRP), von Willebrand factor (vWF).
plasminogen activator inhibitor type I (PAI- 1), and tissue-type plasminogen
activator (t-PA). Furthermore, we assessed the intima-media thickness of the
carotid artery, the distensibility, compliance and stiffness of the carotid artery,
and the flow-mediated vasodilation of the brachial artery as measures of large
artery structure and (endothelial) function. Microalbuminuria, a sign of
generalised endothelial dysfunction, was present in ten ( l2%o) chemotherapy-
treated patients. The prevalence of microalbuminuria in these patients was
significantly different from that in controls (}Vo) and in 3,348 men (age range
28-65 years) from a Dutch population study, in whom microalbuminuria
prevalence was 4.6Vo (95Va confidence interval for difference in proportions
0.37o - 13.7Vo). We also found higher levels of f ibrinogen, hs-CRP, vWF, PAI-
I and t-PA in chemotherapy-treated patients than controls. The difference in
PAI- 1 between chemotherapy-treated patients and controls was much larger
than the difference in t-PA. Furthermore, chemotherapy-treated patients with
an elevated PAI- I concentration (25 out of 90 patients) showed clustering of
cardiovascular risk factors resembling the metabolic syndrome. Measurements
of large artery structure and endothelial function did not differ between groups.
The higher prevalence of microalbuminuria is an important finding in this
survivor population, since microalbuminuria is a predictor of cardiovascular
events. Furthermore, the increased concentrations of hs-CRP and the increased
ratio of PAI- I to t-PA suggest an inflammatory state and a decrease in
fibrinolytic potency. Although these biochemical disturbances were not (yet)
reflected by changes in large artery function and structure, they point to an
increased atherosclerotic risk.
Besides vascular function, chemotherapy may affect cardiac function. In
chapter 5, we investigated left ventricular and cardiac autonomic function to
find out whether cardiac dysfunction contributes to an increased cardiovascular
risk in testicular cancer patients following treatment with chemotherapy.




































patients and 47 healthy controls. We measured plasma levels of N-terminal
pro-brain natriuretic peptide, 24-h ambulatory blood pressure, baroreflex
sensitivity, and cardiac left ventricular function using Doppler
echocardiography. We Íbund that chemotherapy-treated patients had a lower
ratio of early and atrial filling velocities across the mitral valve (E/A-ratio) than
stage I patients and healthy men. The lowerElA-ratio was not only associated
with age and hypertension, but also with chemotherapy treatment. Natriuretic
peptide levels were normal. Baroreflex sensitivity was similar in the three
groups. The decrease in E/A-ratio may indicate impaired relaxation of the left
ventricle. Although the importance of this finding with respect to the risk of
cardiovascular disease is unknown, risk factors known to be associated with
diastolic dysfunction should be treated.
Although direct damage from cytostatic agents to the vasculature has been
proposed as a mechanism behind the development of acute and late
cardiovascular disease in patients with testicular cancer, it was unknown
whether standard vascular tests can be used to detect acute chemotherapy-
induced vascular alterations. In chapter 6, we reported the results of a
prospective study, in which we performed measurements of vascular and
autonomic function in 65 patients with testicular cancer (median age 27 years,
range l8-48 years) prior to and shortly following cisplatin-based
chemotherapy. Before and within ten weeks after completion of chemotherapy,
we measured platelet numbers, plasma levels of fibrinogen, vWF, PAI-l and t-
PA, plasma thrombin activatable fibrinolysis inhibitor (TAFI) activity, 24-h
ambulatory blood pressure, baroreflex sensitivity, intima-media thickness of
the common carotid artery, and flow-mediated vasodilation of the brachial
artery. During treatment, two patients developed a myocardial infarction; at
baseline, these patients had platelet numbers and levels of vWF, t-PA and
fibrinogen above the upper limit of normal, while platelet numbers and vWF
levels increased further during treatment. Overall, we found a significant
increase in the plasma concentration of vWF, but no changes in fibrinogen,
PAI-I, t-PA, and TAFI. Furthermore, the intima-media thickness of the
common carotid artery increased significantly and more than might be expected
from the natural course. Flow-mediated vasodilation and baroreflex sensitivity
did not change. Increases in plasma vWF levels and carotid wall thickness may
indicate chemotherapy-induced vascular damage and be of prognostic
significance tor the development of vascular complications in the long term.
Chemotherapy-related vascular toxicity may result from direct damage to













































































involved in the maintenance of a normal vascular tone, a low inflammatory
state, and a balance between thrombotic and fibrinolytic factors, bleomycin-
and cisplatin-induced damage to endothelial cells may disturb these
homeostatic functions. In chapter 7, we used the immortalized human dermal
microvascular endothelial cell line HMEC- I as an in vitro model to investigate
the effects of bleomycin and cisplatin on the proliferation and apoptosis of
endothelial cells and on their expression of intercellular adhesion molecule- I
(ICAM-l) and the fibrinolytic proteins PAI-I and t-PA. Furthermore, we
investigated potential modulation of cytotoxicity by amifostine and
dexrazoxane. Endothelial cell survival decreased 507a after 0.3 pg/ml
bleomycin and 2.6 pM cisplatin, respectively, which coincided with the
induction of apoptosis. At high concentrations only, amifostine protected
HMEC-l from bleomycin-induced cytotoxicity, while dexrazoxane protected
HMEC-1 from both bleomycin- and cisplatin-induced cytotoxicity. Since both
modulators were also cytotoxic at high concentrations, absolute cell survival
was not increased. Both bleomycin and cisplatin induced upregulation of
ICAM-1 expression. PAI-I was upregulated by bleomycin, while t-PA was
upregulated by both bleomycin and cisplatin. These results indicate that
bleomycin and cisplatin may damage and/or activate endothelial cells, which
may result in the initiation or promotion of inflammation and atherothrombosis
and contribute to the development of vascular events in patients treated with
these cytostatic agents.
Previous studies demonstrated an increased risk for cardiovascular disease
following treatment for testicular cancer. Unfortunately, only cardiovascular
mortality, not morbidity, was investigated in the two largest studies, while
cardiac morbidity can have a serious impact on the quality of life of long-term
survivors and is likely to be of poor prognostic significance. In chapter 8, we
argued that assessment of cardiac mortality only may result in an
underestimation of the importance of cardiac disease as a long-term
complication of treatment, since many cases of cardiac disease may be nonfatal
(initially). This holds true for the determination of cardiac disease risk in long-
term survivors of various malignancies, including testicular cancer.
Bleomycin has proved to be essential for the high treatment efficacy of
standard BEP chemotherapy. However, use of bleomycin is limited by its
potentially life-threatening pulmonary toxicity. This bleomycin-induced
pneumonitis (BIP) is initiated by damage to the lung vasculature by cytokines
and free radicals and can, thus, be viewed as a vascular toxic effect as well.
Known risk factors for bleomycin-induced pneumonitis have proved to be
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inadequate in predicting pulmonary toxicity in the individual patient.
Bleomycin is mainly excreted by the kidneys, but may also be inactivated by
bleomycin hydrolase. In chapter 9, we investigated the relation between an
A1450G polymorphic site in the bleomycin hydrolase gene and the
development of pulmonary toxicity in patients with a disseminated germ cell
tumour following bleomycin-containing chemotherapy in an attempt to identify
a novel tool for predicting an increased risk of pulmonary toxicity in the
individual patient. Data regarding the development of BIP and the presence of
known risk factors for BIP were derived from the medical records and the
bleomycin hydrolase genotype was determined using polymerase chain
reaction and a restriction fragment length polymorphism technique. In 340
patients (8l%o of all testicular cancer patients treated with bleomycin between
1917 and 2003), BIP was present in 38 (l l%o) patients and was fatal in four of
these cases. Patients with BIP had a higher age and a lower pretreatment
creatinine clearance than patients without BIP. The frequencies of BIP were
147o, 87o and l4%o in patients with the A/A, A/G or G/G genotype,
respectively. Therefore, no clear association was found between the bleomycin
hydrolase genotype and the risk of pulmonary toxicity.
Finally, in chapter 10, we have indicated how the results of the above-
mentioned studies fit into current knowledge of chemotherapy-induced
vascular toxicity. Because preventive measures are (still) lacking, we have
further recommended early identification of late vascular toxicity through
periodic screening.
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